91 related articles for article (PubMed ID: 16321833)
1. Correlates of imexon sensitivity in human multiple myeloma cell lines.
Samulitis BK; Landowski TH; Dorr RT
Leuk Lymphoma; 2006 Jan; 47(1):97-109. PubMed ID: 16321833
[TBL] [Abstract][Full Text] [Related]
2. Imexon-induced apoptosis in multiple myeloma tumor cells is caspase-8 dependent.
Evens AM; Prachand S; Shi B; Paniaqua M; Gordon LI; Gartenhaus RB
Clin Cancer Res; 2004 Feb; 10(4):1481-91. PubMed ID: 14977852
[TBL] [Abstract][Full Text] [Related]
3. Induction of mitochondrial changes in myeloma cells by imexon.
Dvorakova K; Waltmire CN; Payne CM; Tome ME; Briehl MM; Dorr RT
Blood; 2001 Jun; 97(11):3544-51. PubMed ID: 11369649
[TBL] [Abstract][Full Text] [Related]
4. Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon.
Dvorakova K; Payne CM; Tome ME; Briehl MM; McClure T; Dorr RT
Biochem Pharmacol; 2000 Sep; 60(6):749-58. PubMed ID: 10930529
[TBL] [Abstract][Full Text] [Related]
5. Molecular and cellular characterization of imexon-resistant RPMI8226/I myeloma cells.
Dvorakova K; Payne CM; Tome ME; Briehl MM; Vasquez MA; Waltmire CN; Coon A; Dorr RT
Mol Cancer Ther; 2002 Jan; 1(3):185-95. PubMed ID: 12467213
[TBL] [Abstract][Full Text] [Related]
6. Induction of apoptosis and cell cycle arrest by imexon in human pancreatic cancer cell lines.
Dorr RT; Raymond MA; Landowski TH; Roman NO; Fukushima S
Int J Gastrointest Cancer; 2005; 36(1):15-28. PubMed ID: 16227632
[TBL] [Abstract][Full Text] [Related]
7. Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines.
Scott J; Dorr RT; Samulitis B; Landowski TH
Cancer Chemother Pharmacol; 2007 May; 59(6):749-57. PubMed ID: 17333195
[TBL] [Abstract][Full Text] [Related]
8. Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro.
Hersh EM; Gschwind CR; Taylor CW; Dorr RT; Taetle R; Salmon SE
J Natl Cancer Inst; 1992 Aug; 84(16):1238-44. PubMed ID: 1640482
[TBL] [Abstract][Full Text] [Related]
9. Imexon activates an intrinsic apoptosis pathway in RPMI8226 myeloma cells.
Dvorakova K; Payne CM; Landowski TH; Tome ME; Halperin DS; Dorr RT
Anticancer Drugs; 2002 Nov; 13(10):1031-42. PubMed ID: 12439337
[TBL] [Abstract][Full Text] [Related]
10. Imexon augments sensitivity of human lymphoma cells to ionizing radiation: in vitro experimental study.
Cho H; Koto M; Riesterer O; Molkentine DP; Giri U; Milas L; Story MD; Ha CS; Raju U
Anticancer Res; 2009 Nov; 29(11):4409-15. PubMed ID: 20032386
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor activity and mechanism of action for a cyanoaziridine-derivative, AMP423.
Dorr RT; Wisner L; Samulitis BK; Landowski TH; Remers WA
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1039-49. PubMed ID: 22186884
[TBL] [Abstract][Full Text] [Related]
12. Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma.
Moehler TM; Feneberg R; Ho AD; Golenkov AK; Ludwig H; Kropff M; Khuageva NK; Hajda J; von Broen I; Goldschmidt H
Anticancer Drugs; 2010 Aug; 21(7):708-15. PubMed ID: 20571355
[TBL] [Abstract][Full Text] [Related]
13. The variable chemotherapeutic response of Malabaricone-A in leukemic and solid tumor cell lines depends on the degree of redox imbalance.
Manna A; De Sarkar S; De S; Bauri AK; Chattopadhyay S; Chatterjee M
Phytomedicine; 2015 Jul; 22(7-8):713-23. PubMed ID: 26141757
[TBL] [Abstract][Full Text] [Related]
14. Chemical basis for the biological activity of imexon and related cyanoaziridines.
Iyengar BS; Dorr RT; Remers WA
J Med Chem; 2004 Jan; 47(1):218-23. PubMed ID: 14695835
[TBL] [Abstract][Full Text] [Related]
15. Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice.
Pourpak A; Meyers RO; Samulitis BK; Sherry Chow HH; Kepler CY; Raymond MA; Hersh E; Dorr RT
Anticancer Drugs; 2006 Nov; 17(10):1179-84. PubMed ID: 17075317
[TBL] [Abstract][Full Text] [Related]
16. Imexon induces an oxidative endoplasmic reticulum stress response in pancreatic cancer cells.
Sheveleva EV; Landowski TH; Samulitis BK; Bartholomeusz G; Powis G; Dorr RT
Mol Cancer Res; 2012 Mar; 10(3):392-400. PubMed ID: 22275514
[TBL] [Abstract][Full Text] [Related]
17. The antitumor agent imexon activates antioxidant gene expression: evidence for an oxidative stress response.
Baker AF; Landowski T; Dorr R; Tate WR; Gard JM; Tavenner BE; Dragovich T; Coon A; Powis G
Clin Cancer Res; 2007 Jun; 13(11):3388-94. PubMed ID: 17545547
[TBL] [Abstract][Full Text] [Related]
18. Chemistry and pharmacology of imexon and related cyanoaziridines.
Remers WA; Dorr RT
Curr Med Chem; 2012; 19(33):5745-53. PubMed ID: 22998528
[TBL] [Abstract][Full Text] [Related]
19. Green tea component, catechin, induces apoptosis of human malignant B cells via production of reactive oxygen species.
Nakazato T; Ito K; Ikeda Y; Kizaki M
Clin Cancer Res; 2005 Aug; 11(16):6040-9. PubMed ID: 16115949
[TBL] [Abstract][Full Text] [Related]
20. Induction of necrosis and apoptosis to KB cancer cells by sanguinarine is associated with reactive oxygen species production and mitochondrial membrane depolarization.
Chang MC; Chan CP; Wang YJ; Lee PH; Chen LI; Tsai YL; Lin BR; Wang YL; Jeng JH
Toxicol Appl Pharmacol; 2007 Jan; 218(2):143-51. PubMed ID: 17196629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
